Abstract
The landscape of systemic therapies (ST) for advanced hepatocellular carcinoma (HCC) pts has evolved in recent years. So far, the IMbrave 150 study (NCT03434379; Finn RS NEJM 2020), with the combination of atezolizumab (atezo) + bevacizumab (bev), obtained the best results regarding overall survival (OS) and progression free survival (PFS) in systemic treatment (ST) naïve pts. Still, data from real life scenario on the safety and efficacy of this therapy is lacking. The aim of the study is to report results of atezo + bev outside RCT focusing on safety and efficacy measures.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
